









Markets
/
Stocks
/
nasdaq-zyme
/

Zymeworks Inc

ZYME

22.720USD

+0.700+3.18%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.72BMarket Cap

LossP/E TTM



Zymeworks Inc

22.720

+0.700+3.18%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Zymeworks Inc

Currency: USD Updated: 2026-02-06

Key Insights

Zymeworks Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 27 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.62.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Zymeworks Inc's Score

Industry at a Glance

Industry Ranking

27 / 392

Overall Ranking

122 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Zymeworks Inc Highlights

StrengthsRisks

Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Growing

The company is in a growing phase, with the latest annual income totaling USD 76.30M.

Undervalued

The company’s latest PE is -26.86, at a low 3-year percentile range.

Held by PRFDX

Star Investor PRFDX holds 4.94K shares of this stock.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

35.615

Target Price

+61.74%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Zymeworks Inc is 8.33, ranking 48 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 27.61M, representing a year-over-year increase of 72.59%, while its net profit experienced a year-over-year increase of 34.33%.

Score

Industry at a Glance

Previous score

8.33

Change



Financials

7.79

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.96

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.38

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Zymeworks Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Zymeworks Inc is 6.92, ranking 201 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -26.86, which is -119.60% below the recent high of 5.26 and -21.57% above the recent low of -32.65.

Score

Industry at a Glance

Previous score

6.92

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 27/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Zymeworks Inc is 8.43, ranking 120 out of 392 in the Biotechnology & Medical Research industry. The average price target is 33.50, with a high of 42.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

8.43

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

35.615

Target Price

+61.74%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Zymeworks Inc

ZYME

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Zymeworks Inc is 7.01, ranking 120 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 24.36 and the support level at 21.53, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.56

Change

0.45

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.046

Sell

RSI(14)

43.836

Neutral

STOCH(KDJ)(9,3,3)

35.123

Neutral

ATR(14)

0.926

Low Volatility

CCI(14)

-53.577

Neutral

Williams %R

67.949

Sell

TRIX(12,20)

-0.431

Sell

StochRSI(14)

64.236

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

22.892

Sell

MA10

22.784

Sell

MA20

23.211

Sell

MA50

24.930

Sell

MA100

21.651

Buy

MA200

17.369

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Zymeworks Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 105.96%, representing a quarter-over-quarter increase of 4.14%. The largest institutional shareholder is The Vanguard, holding a total of 2.32M shares, representing 3.10% of shares outstanding, with 22.66% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

EcoR1 Capital, LLC

22.97M

Rubric Capital Management LP

4.71M

BVF Partners L.P.

3.94M

-8.59%

Morgan Stanley & Co. LLC

3.92M

+8.15%

Redmile Group, LLC

3.71M

-10.72%

BlackRock Institutional Trust Company, N.A.

3.12M

+0.38%

The Vanguard Group, Inc.

Star Investors

2.15M

-12.63%

Perceptive Advisors LLC

2.09M

+63.94%

Vestal Point Capital, LP

1.76M

+53.48%

Blackstone Alternative Asset Management, L.P.

1.62M

-2.44%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Zymeworks Inc is 4.93, ranking 61 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.24. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Zymeworks Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.